14 drugs land on TGA's review desk

An update to the TGA’s list of prescription medicines under review, shows 14 applications were accepted by the regulator in June, including six new drugs and eight new indications.

Three pharmas are seeking to register their new oncology drugs, with Boehringer Ingelheim looking to provide early access to Hernexeos via the provisional registration pathway for adults with non-small cell lung cancer (NSCLC) that cannot be removed by surgery or has spread to other parts of the body and who have HER2 activating mutations.

Another NSCLC drug on the cards is Glenmark Pharmaceuticals’ Velarion, which works by blocking a protein called EGFR.